Subtype
Digestive System Adenocarcinoma
CI-CAN-00002525Explore in graph →
1,373 active trials24 approved drugs77 evidence items
- NCIt
- C210140
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002525Explore in graph →
Clinical trials
5,067 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (618)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07014254 | Therapeutic Study of 177Lu-CTR-FAPI in Advanced Metastatic Digestive Malignancies | not yet recruiting | N/A | 20 | Xijing HospitalOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT07010588 | Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk(SHORT) | not yet recruiting | N/A | 1,389 | Peking University People's HospitalOTHER | 1 | Jun 8, 2025 |
| clinicaltrials |
| NCT07003776 | Evaluation of Tumor Budding In Colorectal Adenocarcinoma | not yet recruiting | — | 50 | Sohag UniversityOTHER | 0 | Jun 4, 2025 | clinicaltrials |
| NCT06998771 | JSKN003 Combined Treatment of HER2-positive Gastric Cancer | not yet recruiting | Phase 2 | 153 | Shanghai JMT-Bio Inc.INDUSTRY | 0 | May 31, 2025 | clinicaltrials |
| NCT06994572 | Study of CT-01 as Monotherapy and Combination Therapy in Subjects With Intermediate or Advanced Hepatocellular Carcinoma | not yet recruiting | Phase 1 | 141 | Captor Therapeutics S.A.INDUSTRY | 0 | May 29, 2025 | clinicaltrials |
| NCT06990620 | TACE Plus Ivonescimab for Unresectable Non-Metastatic HCC(TACE HCC) | not yet recruiting | Phase 1 | 56 | Fudan UniversityOTHER | 0 | May 25, 2025 | clinicaltrials |
| NCT06984718 | A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC | not yet recruiting | Phase 2 | 120 | AkesoINDUSTRY | 0 | May 22, 2025 | clinicaltrials |
| NCT05660213 | A Multicenter Registry Study on Stage III Hepatocellular Carcinoma in Unresectable CNLC Liver Cancer | not yet recruiting | — | 750 | Fudan UniversityOTHER | 0 | May 20, 2025 | clinicaltrials |
| NCT06971107 | Current Microsatellite Stability Results in Colon Cancer | not yet recruiting | — | 1,500 | Turkish Society of Colon and Rectal SurgeryOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT06971237 | SIRT and Peri-immunotherapy : a New Concept(IMSIRT) | not yet recruiting | — | 60 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT06958484 | Iparomlimab and Tuvonralimab Injection (QL1706) Combined With Bevacizumab for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma (HCC) With High Risk of Recurrence | not yet recruiting | Phase 2 | 60 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 0 | May 6, 2025 | clinicaltrials |
| NCT06942767 | Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | not yet recruiting | Phase 2 | 100 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Apr 27, 2025 | clinicaltrials |
| NCT06938451 | Relationship Between FGF19 Overexpression and Disease Prognosis(FGF19) | not yet recruiting | — | 100 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT06935175 | A Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in the Treatment of Advanced Hepatocellular Cancer | not yet recruiting | Phase 2 | 53 | Shanghai Zhongshan HospitalOTHER | 1 | Apr 20, 2025 | clinicaltrials |
| NCT06903663 | The Epidemiology of Patients Treated With ATZ+BEV in Real Life Setting(MANIFEST-HCC) | not yet recruiting | — | 100 | Institutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian FodorOTHER | 1 | Apr 17, 2025 | clinicaltrials |
| NCT06928415 | Efficacy and Safety of Liver Transplantation for Hepatocellular Carcinoma With Bile Duct Tumor Thrombus: a Single-arm, Multicenter, Prospective Study (HCC-BDTT in LT) | not yet recruiting | — | 130 | Zhejiang UniversityOTHER | 0 | Apr 15, 2025 | clinicaltrials |
| NCT06923176 | Effect of Biejia-Ruangan Compound on Survival Rate and Recurrence Rate of Hepatocellular Carcinoma After Radical Treatment(BRCSRRRHCCART) | not yet recruiting | Phase 4 | 704 | Zhiyun YangOTHER | 0 | Apr 11, 2025 | clinicaltrials |
| NCT06919510 | A Phase ll Study of Neoadjuvant Short-course Radiotherapy Followed by Ivonescimab and Chemotherapy in pMMR/MSS Locally Advanced Rectal Cancer | not yet recruiting | Phase 2 | 90 | Sun Yat-sen UniversityOTHER | 0 | Apr 9, 2025 | clinicaltrials |
| NCT06911021 | 68Ga-FAPI-46 in Staging of Pancreatic Adenocarcinoma | not yet recruiting | N/A | 20 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT06911086 | SH-LPS System in Preoperative Planning for Liver Resection | not yet recruiting | Phase 2 / Phase 3 | 100 | Zhejiang Cancer HospitalOTHER | 0 | Apr 4, 2025 | clinicaltrials |
| NCT06900478 | Icariin Soft Capsules Combined With TACE as Adjuvant Therapy for HCC | not yet recruiting | Phase 2 | 25 | Hua LiOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT06896396 | Icaritin Soft Capsules+TACE+Immunotherapy+Targeted Therapy Versus TACE+Immunotherapy+Targeted Therapy for Unresectable Hepatocellular Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 60 | Zhiyong HuangOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT06894524 | Retrospective Clinical Validation of HepatoPredict | not yet recruiting | — | 200 | OphiomicsINDUSTRY | 0 | Mar 25, 2025 | clinicaltrials |
| NCT06888037 | Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric Cancer | not yet recruiting | Phase 2 | 55 | Ruijin HospitalOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT06884982 | An Exploratory Clinical Study on Neoadjuvant Treatment of Hepatocellular Carcinoma with QL1706 Combined with Lenvatinib | not yet recruiting | Phase 2 | 30 | Northern Jiangsu People's HospitalOTHER | 0 | Mar 19, 2025 | clinicaltrials |
| NCT06871527 | Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer | not yet recruiting | Phase 1 / Phase 2 | 44 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT06871930 | Characteristic and Survival Outcomes in Hepatocellular Carcinoma Patients: on Top of Viral Hepatitis Versus Combined Viral and Metabolic-Associated Steatotic Liver Disease | not yet recruiting | — | 150 | Assiut UniversityOTHER | 0 | Mar 12, 2025 | clinicaltrials |
| NCT06872606 | Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for Total Neoadjuvant Therapy of Microsatellite Stable (MSS) Locally Advanced Low Rectal Cancer(SCRIPBOT) | not yet recruiting | Phase 2 | 33 | Sir Run Run Shaw HospitalOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT06743386 | Pilot Study of EUS-Guided Radiofrequency and FOLFIRINOX in Advanced Pancreatic Cancer (RadioFAP )(RadioFAP) | not yet recruiting | N/A | 30 | French Society of Digestive EndoscopyOTHER | 0 | Mar 11, 2025 | clinicaltrials |
| NCT05195294 | Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC | not yet recruiting | Phase 2 | 55 | Lion TCR Pte. Ltd.INDUSTRY | 0 | Mar 10, 2025 | clinicaltrials |
| NCT06867432 | Efficacy and Safety of Yttrium-90 Microspheres Selective Internal Radiotherapy Combined with Immune Checkpoint Inhibitors and Anti-angiogenesis Drugs Sequential HAIC for Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Mar 10, 2025 | clinicaltrials |
| NCT06841185 | A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX13 with YERVOY As a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma | not yet recruiting | Phase 3 | 656 | Shanghai Henlius BiotechINDUSTRY | 0 | Feb 24, 2025 | clinicaltrials |
| NCT06836518 | Sialic Acid in Hepatocellular Carcinoma | not yet recruiting | — | 100 | Sohag UniversityOTHER | 0 | Feb 20, 2025 | clinicaltrials |
| NCT06836778 | Comparative Study of Carvedilol Monotherapy Versus Combination Therapy With Endoscopic Variceal Ligation (EVL) for Primary Prophylaxis of Variceal Bleeding in Patients With Hepatocellular Carcinoma With High-Risk Esophageal Varices | not yet recruiting | N/A | 100 | Institute of Liver and Biliary Sciences, IndiaOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT06822985 | QL1706 As Second-line Treatment in Patients with Advanced Hepatocellular Carcinoma(QL1706) | not yet recruiting | Phase 1 | 21 | Wan-Guang ZhangOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT06823050 | A Prospective, Multicenter, Phase II Clinical Study on the Treatment of Unresectable Advanced HCC with DEB-TACE Combined with SALOX-HAIC | not yet recruiting | — | 59 | Xuhua DuanOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT06750861 | QL1706 Plus Chemotherapy With AG Regime as First-line Treatment of Advanced PDAC | not yet recruiting | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06807112 | The Influence of Secretin Stimulated Pancreatic Secretion on ctDNA Expression in Patients With Pancreatic Ductal Adenocarcinoma: The Role of Biomarkers in Determining the Prognosis of Pancreatic Ductal Adenocarcinoma | not yet recruiting | — | 39 | Charles University, Czech RepublicOTHER | 1 | Feb 4, 2025 | clinicaltrials |
| NCT06798194 | Fusing Ultrasound and Magnetic Resonance Imaging to Intelligently Plan Highly Conformal Ablation Thermal Field for Hepatocellular Carcinoma | not yet recruiting | — | 300 | Chinese PLA General HospitalOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06792097 | Ga-68 Dolacga PET Scan in HCC Under RFA(HCC; RFA) | not yet recruiting | — | 10 | National Taiwan University HospitalOTHER | 0 | Jan 24, 2025 | clinicaltrials |
| NCT06783153 | Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients | not yet recruiting | Phase 1 / Phase 2 | 80 | Mansoura UniversityOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06774768 | Use of Machine-learning Algorithms, Biomarkers and Measures of Quality of Life to Personalize Medical Management of Liver and Heart Transplant Recipients(DARE) | not yet recruiting | — | 1,000 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT06749678 | Effect of Prehabilitation During the Conversion Therapy on Postoperative Outcomes in Unresectable Hepatocellular Carcinoma | not yet recruiting | N/A | 84 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06750159 | The Use of AKR1B10 for Monitoring Postoperative Recurrence of Hepatocellular Carcinoma | not yet recruiting | — | 400 | Peking Union Medical College HospitalOTHER | 0 | Dec 27, 2024 | clinicaltrials |
| NCT06739317 | SBRT Combined with Camrelizumab and Apatinib for Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma. | not yet recruiting | Phase 2 / Phase 3 | 398 | Sun Yat-sen UniversityOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT06724263 | A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors | not yet recruiting | Phase 2 | 120 | Tasly Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT06708650 | Combination of SFRT, PD-L1 Inhibitor, and Anti-VEGF in Advanced Hepatocellular Carcinoma | not yet recruiting | N/A | 50 | Guiping People's HospitalOTHER | 1 | Nov 27, 2024 | clinicaltrials |
| NCT06700564 | The Diagnostic Efficacy and Lesion Detection Advantages of 18F-FDG PET/CT and Enhanced MRI in Hepatic Malignancies | not yet recruiting | — | 60 | Shanghai East HospitalOTHER | 0 | Nov 22, 2024 | clinicaltrials |
| NCT06685354 | Sequential T and I With H101 Via HAI for BCLC C Stage HCC: A Prospective Single-Center Single-Arm Pilot Study | not yet recruiting | Phase 2 | 11 | Henan Cancer HospitalOTHER_GOV | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06666166 | SHR-A1811 Combined with Apatinib in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer | not yet recruiting | Phase 2 | 28 | Yunpeng LiuOTHER | 1 | Oct 30, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jun 10, 2025source: clinicaltrials